Modern directions of radionuclide diagnosis in patients with prostate cancer

P.O. Korol, M.M. Tkachenko


The review of the literature considers the key questions on the history of development and clinical application of modern methods for radionuclide diagnosis in patients with prostate cancer (PCa). The algorithm for making a diagnostic decision in patients with PCa takes into account the multidisciplinary approach to each stage of the process — from setting the primary diagnosis, staging, restaging to prescribing treatment procedures. In this context, nuclear medicine plays a key role when determining the activity of the disease characterizing the tumor in patients with a relapse of PCa from a functional point of view, as well as increasing the level of the prostate-specific antigen. However, further studies are needed to directly compare the new radioactive ligands in the same clinical settings and in the more numerous diagnostic groups that are needed to address the issue of finding the most sensitive markers of PCa and the conditions for their better use.


prostate cancer; prostate-specific antigen; radionuclide diagnosis; review


Ahmadzadehfar H, Rahbar K, Kürpig S, et al. Early side effects and first results of radioligand therapy with 77Lu‑DKFZ‑617 PSMA of castrate‑resistant metastatic prostate cancer: A two‑centre study. EJNMMI Res. 2015 Dec;5(1):114. doi: 10.1186/s13550-015-0114-2.

Attard G, Parker C, Eeles RA, et al. Prostate cancer. Lancet. 2016 Jan 2;387(10013):70-82. doi: 10.1016/S0140-6736(14)61947-4.

Baum RP, Kulkarni HR, Schuchardt C, et al. 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy. J Nucl Med. 2016 Jul;57(7):1006-13. doi: 10.2967/jnumed.115.168443.

Beheshti M, Haim S, Zakavi R, et al. Impact of 18F‑choline PET/CT in prostate cancer patients with biochemical recurrence: Influence of androgen deprivation therapy and correlation with PSA kinetics. J Nucl Med. 2013 Jun;54(6):833-40. doi: 10.2967/jnumed.112.110148.

Benešová M, Schäfer M1, Bauder-Wüst U, et al. Preclinical evaluation of a tailor‑made DOTA‑conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer. J Nucl Med. 2015 Jun;56(6):914-20. doi: 10.2967/jnumed.114.147413.

Calabria F, Gallo G, Schillaci O, Cascini GL. Bio‑distribution, imaging protocols and diagnostic accuracy of PET with tracers of lipogenesis in imaging prostate cancer: A comparison between 11C‑choline, 18F-Fluoroethylcholine and 18F‑methylcholine. Curr Pharm Des. 2015;21(32):4738-47.

Calabria F, Gangemi V, Gullà D, Schillaci O, Cascini GL. 64Cu‑PSMA uptake in meningioma: A potential pitfall of a promising radiotracer. Rev Esp Med Nucl Imagen Mol. 2017 Sep - Oct;36(5):335-336. doi: 10.1016/j.remn.2016.10.002.

Chakraborty PS, Kumar R, Tripathi M, Das CJ, Bal C. Detection of brain metastasis with 68Ga‑labeled PSMA ligand PET/CT: A novel radiotracer for imaging of prostate carcinoma. Clin Nucl Med. 2015 Apr;40(4):328-9. doi: 10.1097/RLU.0000000000000709.

Cho SY, Szabo Z. Molecular imaging of urogenital diseases. Semin Nucl Med. 2014 Mar;44(2):93-109. doi: 10.1053/j.semnuclmed.2013.10.008.

Chondrogiannis S, Marzola MC, Ferretti A, et al. Is the detection rate of 18F‑choline PET/CT influenced by androgen‑deprivation therapy? Eur J Nucl Med Mol Imaging. 2014 Jul;41(7):1293-300. doi: 10.1007/s00259-014-2720-z.

Chondrogiannis S, Marzola MC, Grassetto G, et al. New acquisition protocol of 18F‑choline PET/CT in prostate cancer patients: Review of the literature about methodology and proposal of standardization. Biomed Res Int. 2014;2014:215650. doi: 10.1155/2014/215650.

Cuccurullo V, Di Stasio GD, Evangelista L, Castoria G, Mansi L. Biochemical and pathophysiological premises to positron emission tomography with choline radiotracers. J Cell Physiol. 2017 Feb;232(2):270-275. doi: 10.1002/jcp.25478.

Cuccurullo V, Cascini G, Rossi A, Tamburrini O, Rotondo A, Mansi L. Pathophysiological premises to radiotracers for bone metastases. Q J Nucl Med Mol Imaging. 2011 Aug;55(4):353-73.

Cuccurullo V, Di Stasio GD, Mansi L. Nuclear medicine in prostate cancer: a new era for radiotracers. World J Nucl Med. 2018 Apr-Jun;17(2):70-78. doi: 10.4103/wjnm.WJNM_54_17.

De Marzo AM, Nelson WG, Isaacs WB, Epstein JI. Pathological and molecular aspects of prostate cancer. Lancet. 2003 Mar 15;361(9361):955-64. doi: 10.1016/S0140-6736(03)12779-1.

Demirkol MO, Acar Ö, Uçar B, Ramazanoğlu SR, Sağlıcan Y, Esen T. Prostate‑specific membrane antigen‑based imaging in prostate cancer: Impact on clinical decision making process. Prostate. 2015 May;75(7):748-57. doi: 10.1002/pros.22956.

Evangelista L, Cervino AR, Guttilla A, Zattoni F, Cuccurullo V, Mansi L. ¹⁸F-fluoromethylcholine or ¹⁸F-fluoroethylcholine pet for prostate cancer imaging: Which is better? A literature revision. Nucl Med Biol. 2015 Apr;42(4):340-8. doi: 10.1016/j.nucmedbio.2014.12.019.

Fandella A, Scattoni V, Galosi A, et al. Italian prostate biopsies group: 2016 updated guidelines insights. Anticancer Res. 2017 Feb;37(2):413-424. doi:10.21873/anticanres.11333.

Giesel FL, Sterzing F, Schlemmer HP, et al. Intra‑individual comparison of (68)Ga‑PSMA‑11‑PET/CT and multi‑parametric MR for imaging of primary prostate cancer. Eur J Nucl Med Mol Imaging. 2016 Jul;43(8):1400-6. doi: 10.1007/s00259-016-3346-0.

Grubmüller B, Baum RP, Capasso E, et al. 64Cu‑PSMA‑617 PET/CT imaging of prostate adenocarcinoma: First in‑human studies. Cancer Biother Radiopharm. 2016 Oct; 31(8): 277-286. doi:10.1089/cbr.2015.1964.

Haffner MC, Laimer J, Chaux A, et al. High expression of prostate‑specific membrane antigen in the tumor‑associated neo‑vasculature is associated with worse prognosis in squamous cell carcinoma of the oral cavity. Mod Pathol. 2012 Aug;25(8):1079-85. doi: 10.1038/modpathol.2012.66.

Høilund-Carlsen PF, Poulsen MH, Petersen H, Hess S, Lund L. FDG in urologic malignancies. PET Clin. 2014 Oct;9(4):457-68, vi. doi: 10.1016/j.cpet.2014.07.003.

Hövels AM, Heesakkers RA, Adang EM, et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: A meta‑analysis. Clin Radiol. 2008 Apr;63(4):387-95. doi: 10.1016/j.crad.2007.05.022.

Jadvar H. Is there use for FDG‑PET in prostate cancer? Semin Nucl Med. 2016 Nov;46(6):502-506. doi: 10.1053/j.semnuclmed.2016.07.004.

Karanika S, Karantanos T, Li L, Corn PG, Thompson TC. DNA damage response and prostate cancer: Defects, regulation and therapeutic implications. Oncogene. 2015 May 28;34(22):2815-22. doi: 10.1038/onc.2014.238.

Kitson SL, Kitson SL, Cuccurullo V, Moody TS, Mansi L. Radionuclide antibody‑conjugates, a targeted therapy towards cancer. Curr Radiopharm. 2013 Jun 6;6(2):57-71.

Kratochwil C, Giesel FL, Stefanova M, et al. PSMA‑targeted radionuclide therapy of metastatic castration‑resistant prostate cancer with Lu‑177 labeled PSMA‑617. J Nucl Med. 2016 Aug;57(8):1170-6. doi: 10.2967/jnumed.115.171397.

Lindenberg L, Ahlman M, Turkbey B, Mena E, Choyke P. Advancement of MR and PET/MR in prostate cancer. Semin Nucl Med. 2016 Nov;46(6):536-543. doi: 10.1053/j.semnuclmed.2016.07.001.

Mansi L, Ciarmiello A, Cuccurullo V. PET/MRI and the revolution of the third eye. Eur J Nucl Med Mol Imaging. 2012 Oct;39(10):1519-24. doi: 10.1007/s00259-012-2185-x.

Mansi L, Cuccurullo V, Evangelista L. Is radiocholine PET/CT already clinically useful in patients with prostate cancer? J Nucl Med. 2014 Sep;55(9):1401-3. doi: 10.2967/jnumed.114.142679.

Manyak MJ. Indium‑111 capromab pendetide in the management of recurrent prostate cancer. Expert Rev Anticancer Ther. 2008 Feb;8(2):175-81. doi: 10.1586/14737140.8.2.175.

Maurer MH, Härmä KH, Thoeny H. Diffusion‑weighted genitourinary imaging. Radiol Clin North Am. 2017 Mar;55(2):393-411. doi: 10.1016/j.rcl.2016.10.014.

Maurer T, Schwamborn K, Schottelius M, et al. PSMA theranostics using PET and subsequent radioguided surgery in recurrent prostate cancer. Clin Genitourin Cancer. 2016 Oct;14(5):e549-e552. doi: 10.1016/j.clgc.2016.05.020.

Maurer T, Weirich G, Schottelius M, et al. Prostate‑specific membrane antigen‑radioguided surgery for metastatic lymph nodes in prostate cancer. Eur Urol. 2015 Sep;68(3):530-4. doi: 10.1016/j.eururo.2015.04.034.

Mease RC. Radionuclide based imaging of prostate cancer. Curr Top Med Chem. 2010;10(16):1600-16.

Mertens K, Slaets D, Lambert B, Acou M, De Vos F, Goethals I. PET with (18) F‑labelled choline‑based tracers for tumour imaging: A review of the literature. Eur J Nucl Med Mol Imaging. 2010 Nov;37(11):2188-93. doi: 10.1007/s00259-010-1496-z.

Rahbar K, Schmidt M, Heinzel A, et al. Response and tolerability of a single dose of 177Lu‑PSMA‑617 in patients with metastatic castration‑resistant prostate cancer: A multicenter retrospective analysis. J Nucl Med. 2016 Sep;57(9):1334-8. doi: 10.2967/jnumed.116.173757.

Robu S, Schottelius M, Eiber M, et al. Preclinical Evaluation and First Patient Application of 99mTc‑PSMA‑I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer.  J Nucl Med. 2017 Feb;58(2):235-242. doi: 10.2967/jnumed.116.178939.

Rowe SP, Gorin MA, Allaf ME, et al. PET imaging of prostate‑specific membrane antigen in prostate cancer: Current state of the art and future challenges. Prostate Cancer Prostatic Dis. 2016 Sep;19(3):223-30. doi: 10.1038/pcan.2016.13.

Rowe SP, Macura KJ, Ciarallo A, et al. Comparison of prostate‑specific membrane antigen‑based 18F‑DCFBC PET/CT to conventional imaging modalities for detection of hormone‑naïve and castration‑resistant metastatic prostate cancer. J Nucl Med. 2016 Jan;57(1):46-53. doi: 10.2967/jnumed.115.163782.

Santoni M, Scarpelli M, Mazzucchelli R, et al. Targeting prostate‑specific membrane antigen for personalized therapies in prostate cancer: Morphologic and molecular backgrounds and future promises. J Biol Regul Homeost Agents. 2014 Oct-Dec;28(4):555-63.

Shaish H, Taneja SS, Rosenkrantz AB. Prostate MR imaging: An update. Radiol Clin North Am. 2017 Mar;55(2):303-320. doi: 10.1016/j.rcl.2016.10.011.

Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate‑specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997 Jan;3(1):81-5.

Su HC, Zhu Y, Ling GW, et al. Evaluation of 99mTc‑labeled PSMA‑SPECT/CT imaging in prostate cancer patients who have undergone biochemical relapse. Asian J Androl. 2017 May-Jun;19(3):267-271. doi: 10.4103/1008-682X.192638.

Umbricht CA, Benešová M, Schmid RM, et al. 44Sc‑PSMA‑617 for radiotheragnostics in tandem with 177Lu‑PSMA‑617‑preclinical investigations in comparison with 68Ga‑PSMA‑11 and 68Ga‑PSMA‑617. EJNMMI Res. 2017 Dec;7(1):9. doi: 10.1186/s13550-017-0257-4.

Van Leeuwen PJ, Stricker P, Hruby G, et al. (68) Ga‑PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment. BJU Int. 2016 May;117(5):732-9. doi: 10.1111/bju.13397.

Von Eyben FE, Kairemo K. Acquisition with (11)C‑choline and (18)F‑fluorocholine PET/CT for patients with biochemical recurrence of prostate cancer: A systematic review and meta‑analysis. Ann Nucl Med. 2016 Jul;30(6):385-92. doi: 10.1007/s12149-016-1078-7.

Yu CY, Desai B, Ji L, Groshen S, Jadvar H. Comparative performance of PET tracers in biochemical recurrence of prostate cancer: A critical analysis of literature. Am J Nucl Med Mol Imaging. 2014 Sep 6;4(6):580-601.

Zang S, Shao G, Cui C, et al. 68Ga‑PSMA‑11 PET/CT for prostate cancer staging and risk stratification in Chinese patients. Oncotarget. 2017 Feb 14;8(7):12247-12258. doi: 10.18632/oncotarget.

Copyright (c) 2020 P.O. Korol, M.M. Tkachenko

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.


© "Publishing House "Zaslavsky", 1997-2020


   Seo анализ сайта